Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)
Abstract Background Targeted lung denervation (TLD) is a bronchoscopically delivered ablation therapy that selectively interrupts pulmonary parasympathetic nerve signaling. The procedure has the potential to alter airway smooth muscle tone and reactivity, decrease mucous secretion, and reduce airway...
Main Authors: | Dirk-Jan Slebos, Bruno Degano, Arschang Valipour, Pallav L. Shah, Gaetan Deslée, Frank C. Sciurba, on behalf of the AIRFLOW-3 Trial Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-020-1058-5 |
Similar Items
-
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
by: Pison Christophe, et al.
Published: (2021-02-01) -
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
by: Valipour A, et al.
Published: (2020-11-01) -
Long-term safety of bilateral targeted lung denervation in patients with COPD
by: Valipour A, et al.
Published: (2018-07-01) -
Key Components of Human Myofibre Denervation and Neuromuscular Junction Stability are Modulated by Age and Exercise
by: Casper Soendenbroe, et al.
Published: (2020-04-01) -
Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
by: Christophe Pison, et al.
Published: (2021-03-01)